Strategic partnerships IACTA leverages ongoing collaborations with external entities (Pharmaleads, TALLC, Ora) to advance ophthalmic assets, suggesting a sales approach that highlights partnership-friendly licensing and co-development opportunities for eye care technologies.

Early-stage funding With modest revenue and a recent $1M government funding, there is potential for targeted sponsorships, grant-aligned programs, or joint grant-funded trials that align with their preclinical ophthalmic pain relief and DENKI assets.

Ophthalmic focus The company specializes in innovative eye care technologies and unmet needs in ophthalmology, opening doors for selling specialized ophthalmic drug delivery systems, analytics, and companion products that enhance efficacy and safety.

Strategic SAB growth Expansion of the Scientific Advisory Board indicates a push for credibility and specialized guidance; opportunities exist to offer high-value advisory services, clinical strategy support, and market access insights to accelerate asset development.

Market positioning Smaller team size with global collaboration signals a need for scalable solutions, including CRO partnerships, outsourcing of regulatory and clinical operations, and cost-effective commercialization pathways for ophthalmic products.